Therefore, this multicenter retrospective study examined whether first-line CIT for NSCLC would provide better OS and PFS than SEQ in advanced NSCLC with PD-L1 expression of ≤49%. This evidence concerns the gene CD274 and non-small cell lung carcinoma.